IP Library Granted Patent US 7,569,697
Granted Patent B2
US 7,569,697 · App. 12/006,845 · Granted Aug 4, 2009

Benzimidazole compound crystal

Assignee: Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,569,697
App. No.
12/006,845
Granted
Aug 4, 2009
Kind
B2
Abstract

A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl],sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.

Claims (4)

1. A method for manufacturing a preparation for oral administration, which comprises:

formulating a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof and a pharmaceutically acceptable carrier into a first composition; and

subsequently forming the preparation for oral administration.

2. The method according to claim 1 wherein the X-ray powder diffraction analysis pattern of the crystal has characteristic peaks at the interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41, and 3.11 Angstrom.

Priority Claims (1)
JP 11-171509 · Jun 17, 1999 · national
Continuity (5)
Continuation 1114990300 · Jun 10, 2005
Continuation 1065511400 · Sep 4, 2003
Continuation 1024332900 · Sep 13, 2002
Continuation 0967462400
Related Publication 20080132547A1 · Jun 5, 2008